January 23, 2013
James Feliciano, Commercial Director of Merck Serono Merck Serono aims to join the top 10 companies in the field of oncology in Japan, making the recently approved additional indication for Erbitux (cetuximab) a steppingstone. The company will promote Erbitux as...read more